2,7-Dimethyl-2-azaspiro<4.5>decan | 702-68-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2,7-Dimethyl-2-azaspiro<4.5>decan
• 英文别名: 2,7-dimethyl-2-aza-spiro[4.5]decane；2,7-Dimethyl-2-azaspiro[4.5]decane
• CAS: 702-68-1
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: CIXYITYGIVHZPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS FLUORÉS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2016144703A1

  公开（公告）日：2016-09-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述的是一种LOXL2抑制剂化合物，制备这种化合物的方法，包含这种化合物的药物组合物和药物，以及使用这种化合物治疗与LOXL2活性相关的疾病、病症或疾病的方法。
• [EN] LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2016144702A1

  公开（公告）日：2016-09-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了一些LOXL2抑制剂化合物，制备这些化合物的方法，包括这些化合物的药物组合物和药物剂以及在治疗与LOXL2活性相关的疾病、疾病或紊乱的方法。
• LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
  申请人：Pharmakea, Inc.

  公开号：EP3265445B1

  公开（公告）日：2021-05-05
• FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
  申请人：Pharmakea, Inc.

  公开号：EP3265456B1

  公开（公告）日：2020-11-18
• PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES
  申请人：LEAD DISCOVERY CENTER GMBH

  公开号：US20150111873A1

  公开（公告）日：2015-04-23

  Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.